Speeding the development of new therapies and diagnostics for glaucoma patients
Glaucoma Research Foundation thanks the following sponsors for their generous support:

Platinum Sponsors

Alcon
ALLERGAN
BAUSCH + LOMB
Ora

Gold Sponsors

aerie pharmaceuticals, inc.
Shire

Silver Sponsors

CARL ZEISS MEDITEC
GLAUKOS
HAAG-STREIT USA
THE LINK FAMILY
New World Medical, Inc.
Santen
SUN OPHTHALMICS

Bronze Sponsors

Akorn Pharmaceuticals
Beaver-Visitec International, Inc.
Diopsys
Ellex
Heidelberg Engineering, Inc.
Icare USA
Inotek Pharmaceuticals
Iridex
Katena IOP
Lumenis
Mobius Therapeutics, LLC
Nidek
NovaBay Pharmaceutical, Inc.
Ophthalmic Mutual Insurance Company
Optovue
Transcend Medical, Inc.
Voxeleron

Wi-Fi sponsored by Ora® — Password: GRF360
Welcome

It is our sincere pleasure to welcome you to the 5th Annual Glaucoma 360: New Horizons Forum.

This catalyst meeting, hosted by Glaucoma Research Foundation, highlights the many unmet medical needs that remain in the field of glaucoma and brings together the essential elements needed to advance the development of new ideas into clinical practice to prevent and manage the disease more effectively. With the overwhelming success of our previous meetings, this annual forum continues to grow and provides the ultimate opportunity for collaboration and networking needed to advance new concepts to reality for glaucoma patients.

Our meeting objectives today are to:

- Bring together nationally and internationally respected leaders in medicine, science, business, venture capital, and the FDA to present and discuss new and emerging ideas in the field of glaucoma therapy.
- Facilitate collaboration between these essential groups in order to accelerate the development and approval of the next generation of therapies and diagnostic devices.
- Broaden our understanding of glaucoma from various sectors engaged in research and development to advance new and effective options to help patients preserve their sight.

Today would not be possible without the generous and selfless contributions of so many including: members of our Advisory Board and Program Committee who have volunteered their time to build an outstanding agenda; our dedicated sponsors who have helped to underwrite this event; our speakers, presenters, and panelists who are ready to share their expertise and unique perspectives; our attendees; the support of our Board of Directors and staff at Glaucoma Research Foundation; and the hard working team at The Palace Hotel.

Over the past five years, there have been many advances in the glaucoma space including the development of novel treatments, introduction of new companies, important acquisitions and mergers, as well as several IPO’s. As a result, the field has grown substantially and provides doctors and patients with more options to treat and manage the disease. Thank you for your ongoing involvement in this important initiative to speed the development of new glaucoma drugs, devices, and drug delivery systems to help preserve sight.

All proceeds from Glaucoma 360 events will support Glaucoma Research Foundation’s sight-saving endeavors such as the Catalyst for a Cure, a unique collaborative approach to uncover new diagnostic and treatment options for glaucoma. Together, we can truly make a difference for people living with glaucoma.

Thank you, once again, for your partnership in this important endeavor.

Adrienne Graves, PhD  
Co-Founder, Co-Chair  
New Horizons Forum  
Director,  
Glaucoma Research Foundation

Andrew G. Iwach, MD  
Co-Founder, Co-Chair  
New Horizons Forum  
Board Chair,  
Glaucoma Research Foundation
## Program and Speakers

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 – 8:00 am</td>
<td>Breakfast and Exhibits</td>
</tr>
<tr>
<td>8:00 – 8:06 am</td>
<td>Welcome and Opening Remarks</td>
</tr>
<tr>
<td></td>
<td>Adrienne Graves, PhD and Andrew G. Iwach, MD, Co-Founders and Co-Chairs, Glaucoma 360</td>
</tr>
<tr>
<td>8:06 – 8:32 am</td>
<td>Opening Keynote Address: Drs. Henry and Frederick Sutro Memorial Lecture</td>
</tr>
<tr>
<td></td>
<td>&quot;Bullish on Glaucoma, A 30-Year Perspective on Patient Care, Clinical Research, and Industry&quot;</td>
</tr>
<tr>
<td></td>
<td>Richard A. Lewis, MD, Co-Founder, Sacramento Eye Consultants; Former Director of Glaucoma, University of California, Davis; President, American Society of Cataract and Refractive Surgery, Past President, American Glaucoma Society</td>
</tr>
<tr>
<td></td>
<td>Morning Catalyst: Alan Crandall, MD, Presidential Professor of Ophthalmology and Visual Services, Senior Vice Chair, Director of Glaucoma and Cataract; Co-Director, Division of International Ophthalmology, John A. Moran Eye Center</td>
</tr>
<tr>
<td>8:32 – 9:10 am</td>
<td>New Horizons in Glaucoma Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td>Moderators: Stuart B. Abelson, MBA, President and CEO, Ora, Inc.</td>
</tr>
<tr>
<td></td>
<td>Ruth D. Williams, MD, President, Wheaton Eye Clinic</td>
</tr>
<tr>
<td></td>
<td>Presenting Companies:</td>
</tr>
<tr>
<td></td>
<td>• Aerie Pharmaceuticals—Thomas Mitro, President and COO</td>
</tr>
<tr>
<td></td>
<td>• Bausch + Lomb—Jason Vittitow, PhD, Director, Clinical Affairs</td>
</tr>
<tr>
<td></td>
<td>• Inotek Pharmaceuticals—Cadmus C. Rich, MD, MBA, CPE, VP, Medical Affairs and Clinical Development</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A</td>
</tr>
<tr>
<td>9:10 – 9:15 am</td>
<td>Industry Spotlight: Bausch + Lomb</td>
</tr>
<tr>
<td></td>
<td>Speaker: Tracy M. Valorie, BS, MBA, SVP, General Manager of Ophthalmology Rx, Bausch + Lomb Pharmaceuticals</td>
</tr>
<tr>
<td>9:15 – 9:55 am</td>
<td>FDA: Getting to New Horizons</td>
</tr>
<tr>
<td></td>
<td>Moderators: Eugene de Juan, Jr., MD, Founder and Vice Chairman, ForSight Labs</td>
</tr>
<tr>
<td></td>
<td>Kuldev Singh, MD, MPH, Professor Ophthalmology, Director, Glaucoma Service, Stanford University School of Medicine</td>
</tr>
<tr>
<td></td>
<td>Speakers:</td>
</tr>
<tr>
<td></td>
<td>• Wiley Chambers, MD, Supervisory Medical Officer, Division of Transplant &amp; Ophthalmology Products, FDA</td>
</tr>
<tr>
<td></td>
<td>• Malvina Eydelman, MD, Division Director, Division of Ophthalmic Device Evaluation, FDA</td>
</tr>
<tr>
<td>9:55 – 10:20 am</td>
<td>Break, Exhibits and Networking Opportunity</td>
</tr>
<tr>
<td>10:20 – 11:00 am</td>
<td>Funding Innovation: Securing Capital to Finance Your Start-up</td>
</tr>
<tr>
<td></td>
<td>Speaker/Moderator: Emmett Cunningham, Jr., MD, PhD, MPH, Partner, Clarus Ventures</td>
</tr>
<tr>
<td></td>
<td>Moderator: Richard L. Lindstrom, MD, Founder, Minnesota Eye Consultants, PA</td>
</tr>
<tr>
<td></td>
<td>Panelists:</td>
</tr>
<tr>
<td></td>
<td>• Mark Blumenkranz, MD, MMS, Professor of Ophthalmology, Byers Eye Institute, Stanford University</td>
</tr>
<tr>
<td></td>
<td>• Wende Hutton, Partner, Canaan Partners</td>
</tr>
<tr>
<td></td>
<td>• Gil Kliman, MD, Managing Director, InterWest Partners</td>
</tr>
<tr>
<td></td>
<td>• Christy Shaffer, PhD, Partner, Hatteras Ventures</td>
</tr>
<tr>
<td></td>
<td>• Russ Trenary, President and CEO, InnFocus, Inc.</td>
</tr>
<tr>
<td>11:00 – 11:08 am</td>
<td>Industry Spotlight: Allergan, Inc.</td>
</tr>
<tr>
<td></td>
<td>Speaker: Yehia Hashad, MD, VP—Clinical Development and Global Head of Ophthalmology</td>
</tr>
<tr>
<td>11:08 – 12:15 pm</td>
<td>New Horizons in Glaucoma Drug Delivery</td>
</tr>
<tr>
<td></td>
<td>Moderators: Eliot Lazar, MD, President, eCON Medical</td>
</tr>
<tr>
<td></td>
<td>Paul Schacknow, MD, PhD, Consultant in Glaucoma, East Florida Eye Institute, Clinical Associate Professor, Division of Ophthalmology,</td>
</tr>
<tr>
<td></td>
<td>Presenting Companies:</td>
</tr>
<tr>
<td></td>
<td>• Envisia Therapeutics—Benjamin Yerxa, PhD, President</td>
</tr>
<tr>
<td></td>
<td>• ForSight VISIONS—James D. Brandt, MD, Professor of Ophthalmology &amp; Vision Science, Director of Glaucoma Service, University of California, Davis</td>
</tr>
<tr>
<td></td>
<td>• GrayBug—Jeff Cleland, PhD, Interim CEO</td>
</tr>
<tr>
<td></td>
<td>• Massachusetts Eye and Ear/Harvard Medical School—Joseph B. Ciolino, MD, Assistant Professor of Ophthalmology</td>
</tr>
<tr>
<td></td>
<td>• Ocular Therapeutix, Inc.—Amar Sawhney, PhD, President and CEO</td>
</tr>
<tr>
<td></td>
<td>• Ohr Pharmaceutical Inc.—Barbara Wirostko, MD, VP of Clinical Development</td>
</tr>
<tr>
<td></td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>
**Program and Speakers**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15 – 1:15 pm</td>
<td>Networking Buffet Luncheon</td>
</tr>
<tr>
<td></td>
<td><strong>Afternoon Catalyst:</strong> Gary Novack, PhD, President, PharmaLogic Development, Inc.; Visiting Professor of Pharmacology and Ophthalmology, University of California, Davis, School of Medicine</td>
</tr>
<tr>
<td>1:15 – 1:28 pm</td>
<td>Networking Buffet Luncheon</td>
</tr>
<tr>
<td></td>
<td><strong>Building a Franchise in Ophthalmology—The Allergan Experience</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker: David E.I. Pyott, CBE, Former Chairman of the Board and Chief Executive Officer (1998–2015), Allergan, Inc.</td>
</tr>
<tr>
<td>1:28 – 2:15 pm</td>
<td>Industry Panel Discussion: Glaucoma Devices and Pharmaceuticals</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> K. Angela Macfarlane, JD, President and CEO, ForSight Labs</td>
</tr>
<tr>
<td></td>
<td>Cynthia Mattox, MD, FACS, Director, Glaucoma and Cataract Service, New England Eye Center; Associate Professor and Vice Chair for Clinical Services, Department of Ophthalmology, Tufts University School of Medicine</td>
</tr>
<tr>
<td></td>
<td><strong>Panelists:</strong></td>
</tr>
<tr>
<td></td>
<td>- Aerie Pharmaceuticals, Inc.—Thomas Mitro, President and COO</td>
</tr>
<tr>
<td></td>
<td>- Alcon Laboratories—Emmanuel M. Mahlis, MD, Head, Pharma Medical Affairs, US/Canada</td>
</tr>
<tr>
<td></td>
<td>Clinical &amp; Regulatory Affairs</td>
</tr>
<tr>
<td></td>
<td>- Allergan, Inc.—Aziz Mottiwala, VP of Marketing, US Eye Care</td>
</tr>
<tr>
<td></td>
<td>- Bausch + Lomb—Tracy M. Valorie, BS, MBA, SVP, GM of Ophthalmology Rx</td>
</tr>
<tr>
<td></td>
<td>- Carl Zeiss Meditec, Inc.—Ralf Kuschnereit, PhD, President and CEO</td>
</tr>
<tr>
<td></td>
<td>- Glaukos Corporation—Chris M. Calcaterra, Chief Commercial Officer</td>
</tr>
<tr>
<td></td>
<td>- Haag-Streit USA—Gina DellaCqua, VP, Specialty Diagnostics Division</td>
</tr>
<tr>
<td></td>
<td>- New World Medical, Inc.—Bilal Khan, VP and COO</td>
</tr>
<tr>
<td></td>
<td>- Sun Pharma—Mark C. Jasek, PhD, VP, Medical &amp; Scientific Affairs, Ophthalmics and Neurologics</td>
</tr>
<tr>
<td>2:15 – 3:08 pm</td>
<td>New Horizons in Glaucoma Devices</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong></td>
</tr>
<tr>
<td></td>
<td>- Malik Y. Kahook, MD, Slater Family Endowed Chair of Ophthalmology, Vice Chair, Clinical &amp; Translational Research; Chief, Glaucoma Service &amp; Director, Glaucoma Fellowship, Professor of Ophthalmology, University of Colorado Aschutz Medical Campus</td>
</tr>
<tr>
<td></td>
<td>- Steven D. Vold, MD, Founder and CEO, Vold Vision; Chief Medical Editor, <em>Glaucoma Today</em></td>
</tr>
<tr>
<td></td>
<td><strong>Presenting Companies:</strong></td>
</tr>
<tr>
<td></td>
<td>- Equinox LLC—John Berdahl, MD, CEO and Founder</td>
</tr>
<tr>
<td></td>
<td>- InnFocus, Inc.—Russ Trenary, President and CEO</td>
</tr>
<tr>
<td></td>
<td>- MicroOptx—Chris Pulling, CEO</td>
</tr>
<tr>
<td></td>
<td>- New World Medical, Inc.—Ahmad A. Aref, MD, Professor of Ophthalmology, University of Illinois Chicago</td>
</tr>
<tr>
<td></td>
<td>- Sanoculis—Nir Israeli, CEO</td>
</tr>
<tr>
<td>3:08 – 3:33 pm</td>
<td>Break, Exhibits and Networking Opportunity</td>
</tr>
<tr>
<td>3:33 – 3:55 pm</td>
<td>Update from Glaucoma Research Foundation: Biomarkers in Glaucoma</td>
</tr>
<tr>
<td></td>
<td><strong>Speakers:</strong></td>
</tr>
<tr>
<td></td>
<td>- Tom Brunner, President and CEO, Glaucoma Research Foundation</td>
</tr>
<tr>
<td></td>
<td>- Vivek Srinivasan, PhD, Assistant Professor of Biomedical Engineering at the University of California, Davis</td>
</tr>
<tr>
<td>3:55 – 4:03 pm</td>
<td>Industry Spotlight: Alcon Laboratories</td>
</tr>
<tr>
<td></td>
<td><strong>Speaker</strong></td>
</tr>
<tr>
<td></td>
<td>- Emmanuel M. Mahlis, MD, Head of US/Canada Pharma Medical Affairs</td>
</tr>
<tr>
<td>4:03 – 5:08 pm</td>
<td>New Horizons in Glaucoma Treatment: From Vision Restoration to Optic Nerve Regeneration</td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong></td>
</tr>
<tr>
<td></td>
<td>- Anthony P. Adamis, MD, VP, Global Head of Ophthalmology, Genentech, Inc.</td>
</tr>
<tr>
<td></td>
<td>- L. Jay Katz, MD, Director, Glaucoma Service, Wills Eye Hospital, Ophthalmology Professor, Jefferson Medical College</td>
</tr>
<tr>
<td></td>
<td><strong>Speakers:</strong></td>
</tr>
<tr>
<td></td>
<td>- Larry Benowitz, PhD, Director, Laboratories for Neuroscience Research in Neurosurgery, Boston Children’s Hospital and Professor of Neurosurgery and Ophthalmology, Harvard Medical School</td>
</tr>
<tr>
<td></td>
<td>- Kapil Bharti, PhD, Stadtman Investigator, Unit of Ocular Stem Cell &amp; Translational Research, National Eye Institute</td>
</tr>
<tr>
<td></td>
<td>- Bernhard A. Sabel, PhD, Director, Institute of Medical Psychology at Otto-von-Guericke University of Magdeburg</td>
</tr>
<tr>
<td></td>
<td><strong>Presenting Companies:</strong></td>
</tr>
<tr>
<td></td>
<td>- EBS Technologies GmbH—Jens Ellrich, MD, PhD, Chief Medical Officer</td>
</tr>
<tr>
<td></td>
<td>- Neurotech Pharmaceuticals, Inc.—Charles Johnson, MD Chief Medical Officer</td>
</tr>
<tr>
<td></td>
<td>- Ocata Therapeutics—Eddy Anglade, MD, Chief Medical Officer</td>
</tr>
<tr>
<td>5:08 – 5:17 pm</td>
<td>Forum Summation: Robert D. Fechtner, MD, Director, Glaucoma Division, Department of Ophthalmology and Visual Sciences, Rutgers New Jersey</td>
</tr>
<tr>
<td>5:17 – 5:19 pm</td>
<td>Closing Remarks: Adrienne L. Graves, PhD and Andrew G. Iwach, MD</td>
</tr>
<tr>
<td>5:30 – 6:30 pm</td>
<td>Reception, Exhibits, and Networking</td>
</tr>
</tbody>
</table>
Advisory Board

Stuart B. Abelson, MBA
President and Chief Executive Officer,
Ora, Inc.

Anthony P. Adamis, MD
Vice President,
Global Head of Ophthalmology,
Genentech, Inc.

Ernest Cavin, PhD
President,
Haag-Streit USA

Paul Chaney
President and Chief Executive Officer,
PanOptica, Inc.

George A. Cioffi, MD
Chairman,
Department of Ophthalmology
Columbia University College
of Physicians and Surgeons

Alan S. Crandall, MD
Presidential Professor of Ophthalmology and
Visual Services
Senior Vice Chair, Director of Glaucoma and Cataract
Co-Director, Division of International Ophthalmology,
John A. Moran Eye Center

Emmett Cunningham, Jr., MD, PhD, MPH
Partner,
Clarus Ventures

Eugene de Juan, Jr., MD
Founder and Vice-Chairman,
ForSight Labs

David Guyer, MD
Partner
SV Life Sciences Advisers, LLC

Eve Higginbotham, SM, MD
Vice Dean,
Perelman School of Medicine,
University of Pennsylvania

H. Dunbar Hoskins, Jr., MD
Co-Founder and Director,
Glaucoma Research Foundation
Former Executive Vice President,
American Academy of Ophthalmology

Wende Hutton
General Partner,
Canaan Partners

Ralf Kuschnereit, PhD
President and Chief Executive Officer,
Carl Zeiss Meditec, Inc.

Eliot Lazar, MD
President,
eCON Medical

Paul Lee, MD, JD
F. Bruce Fralick Professor and Chair,
Department of Ophthalmology and Visual Sciences
Director, W.K. Kellogg Eye Center,
University of Michigan

Richard L. Lindstrom, MD
Founder,
Minnesota Eye Consultants, PA

William J. Link, PhD
Managing Director,
Versant Ventures

Cynthia Mattox, MD, FACS
Director of the Glaucoma and Cataract Service,
New England Eye Center
Associate Professor and Vice-Chair,
Department of Ophthalmology
Tufts University School of Medicine
Advisory Board

James Mazzo
Operating Partner
Versant Ventures
Chairman and Chief Executive Officer,
AcuFocus

George Spaeth, MD
Louis Esposito Research Professor
of Ophthalmology
Wills Eye Hospital/Jefferson Medical College

J. Casey McGlynn, JD
Partner,
Wilson Sonsini Goodrich & Rosati

Ellen Strahlman, MD, MHS
Chief Medical Officer and Senior Vice President,
Research and Development,
Becton, Dickinson & Company

Gary D. Novack, PhD
President,
PharmaLogic Development, Inc.

Tracy M. Valorie, BS, MBA
Senior Vice President,
General Manager of Ophthalmology Rx
Bausch + Lomb Pharmaceuticals

David E.I. Pyott, CBE
Former Chairman of the Board,
President and Chief Executive Officer,
Allergan, Inc.

Robert N. Weinreb, MD
Chairman and Director, Shiley Eye Center,
Director, Hamilton Glaucoma Center,
University of California, San Diego

Thomas W. Samuelson, MD
Founding Partner, Minnesota Eye Consultants
Adjunct Associate Professor of
Ophthalmology, University of Minnesota

Ruth D. Williams, MD
President,
Wheaton Eye Clinic

Kuldev Singh, MD, MPH
Professor of Ophthalmology and Director,
Glaucoma Service
Stanford University Medical Center

M. Roy Wilson, MD, MS
President,
Wayne State University

NEW HORIZONS FORUM

Sincere Thanks to Our Media and Strategic Partners

Bryn Mawr Communications
Elsewhere Advertising
International Business Forum
Market Scope

Ophthalmology Innovation Summit
Ophthalmology Times
Wilson Sonsini Goodrich & Rosati
Meet the **Bold new Allergan**

We are a bold new healthcare company. We are one team of dedicated employees, carving new paths, taking bold, decisive actions to deliver results and better outcomes for patients and providers.

We work in a fast-changing industry. We thrive in this environment. We know that change = opportunity, and we are prepared to lead change. We bring new ideas to render a powerful impact on human lives around the world.

We love what we do. We have momentum. This is our moment.

*We are the new Allergan.*

[www.Allergan.com](http://www.Allergan.com)
Program Committee

Ike Ahmed, MD, FRCSC  
Assistant Professor, Faculty of Medicine, University of Toronto  
Clinical Assistant Professor, University of Utah

Eydie G. Miller-Ellis, MD  
Professor of Clinical Ophthalmology, Scheie Eye Institute, University of Pennsylvania

Lama A. Al-Aswad, MD  
Associate Professor of Ophthalmology, Columbia University Medical Center

Mildred M.G. Olivier, MD  
Associate Clinical Professor, Rosalind Franklin University of Medicine and Science  
Associate Clinical Professor, Midwestern University  
Chief Executive Officer and Founder, Midwest Glaucoma Center, P.C.

Anne L. Coleman, MD, PhD  
Frances and Ray Stark Professor of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine at UCLA  
Professor of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles

Joel S. Schuman, MD, FACS  
Chairman of Ophthalmology, New York University

Robert D. Fechtner, MD  
Professor, Institute of Ophthalmology and Visual Science, Director, Glaucoma Division, UMDNJ-New Jersey Medical School

Robert Stamper, MD  
Professor of Clinical Ophthalmology, Director, Glaucoma Service, University of California, San Francisco

Larry Haimovitch  
Founder, Haimovitch Medical Technology Consultants

James C. Tsai, MD, MBA, FACS  
Chair of Ophthalmology, Mount Sinai Health System  
President, New York Eye & Ear Infirmary

L. Jay Katz, MD  
Director, Glaucoma Service, Wills Eye Hospital  
Professor of Ophthalmology, Thomas Jefferson University

Steven Vold, MD  
Founder and Chief Executive Officer, Vold Vision  
Chief Medical Editor, Glaucoma Today

Richard A. Lewis, MD  
Sacramento Eye Consultants  
Former Director of Glaucoma, University of California, Davis

Barbara Wirostko, MD  
Clinical Adjunct Associate Professor, University of Utah School of Medicine

Shan Lin, MD  
Professor of Clinical Ophthalmology, Director, Glaucoma Service, and Director, Glaucoma Fellowship Program, Department of Ophthalmology, University of California, San Francisco
Adrienne Graves, PhD is a visual scientist by training and a global industry leader in ophthalmology. From 2002 to 2010 Dr. Graves was President and CEO of Santen Inc., the US arm of Japan’s largest ophthalmic pharmaceutical company. Prior to joining Santen, Dr. Graves spent nine years with Alcon Laboratories in various Research & Development roles including Director of International Ophthalmology.

She is also a Director on several Foundation Boards including American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology (AAO) Foundation (Emeritus), KeepYourSight, and Himalayan Cataract Project. She also serves on the Corporation Committee for the Brown University Medical School. Dr. Graves is a co-founder of Ophthalmic Women Leaders (OWL) and Glaucoma 360. She received the 2015 Catalyst Award from Glaucoma Research Foundation for her dedication and leadership in advancing ophthalmic innovation.

Dr. Graves did her undergraduate studies at Brown University, her PhD work at the University of Michigan, and a postdoctoral fellowship in visual neuroscience at the University of Paris.

Andrew G. Iwach, MD is the Executive Director, Glaucoma Center of San Francisco and Executive Director, Glaucoma Research and Education Group, Co-Founder and Co-Chair, Glaucoma 360, Chair, Board of Directors, Glaucoma Research Foundation.

Dr. Iwach has been a member on the Board of Directors for the Glaucoma Research Foundation since 2000 and is currently serving as its Chair. He is Co-Founder of the Eye Surgery Center of San Francisco.

He currently serves as a scientific reviewer for many top professional publications, and in 2004 he received the Academy’s Senior Achievement Award and in 2012 the Academy’s Secretariat Award.

Dr. Iwach is an Associate Clinical Professor of Ophthalmology in the Department of Ophthalmology at the University of California San Francisco.

He is on the clinical faculty at California Pacific Medical Center. He teaches courses and lectures extensively on glaucoma. Dr. Iwach is actively involved in clinical research, as well and his focus has included mitomycin-C use in filtering surgery, application of optical coherence tomography in glaucoma, selective laser trabeculoplasty, numerous drug trials and more.

He has published more than 40 peer-reviewed papers and book chapters.

H. Dunbar Hoskins, Jr., MD is an internationally recognized glaucoma specialist and was the Executive Vice President of the American Academy of Ophthalmology from January 1, 1993 to March 31, 2009. He received an Academy Honor Award in 1979, a Senior Honor Award in 1989, and Distinguished Service Award in 1999.

He has held numerous positions in ophthalmology, medicine and business including: Founding Director of the American Glaucoma Society, founder and Director of the Glaucoma Research Foundation, Secretary-Treasurer of the Pan American Association of Ophthalmology, and Chairman of the Advisory Committee to the International Council of Ophthalmology.

He is a Clinical Professor of Ophthalmology at the University of California School of Medicine, San Francisco, where he did his Glaucoma Fellowship.

Dr. Hoskins received his medical degree at the Medical College of Virginia. He was certified by the American Board of Ophthalmology in 1970. He served as Chief of Ophthalmology at the Naval Hospital in Rhode Island in 1968.

Thomas M. Brunner joined Glaucoma Research Foundation in 2003 after a successful 30-year career in the ophthalmic laser business. He helped introduce major advances in eye care including laser photocoagulation to prevent vision loss from diabetic retinopathy, laser treatment of secondary cataracts, and laser treatment for glaucoma.

Since joining Glaucoma Research Foundation, Tom has helped to more than double revenue and focus on innovative research to understand how glaucoma steals sight and find a cure. He received a “Lifetime Achievement” award from the American Society for Laser Medicine and Surgery for his contributions and 25 years of service on their Board of Directors.

Tom actively supports development of new products to help those with glaucoma and other eye diseases as an advisor or board member for startup companies in the eye care field. He graduated from Lehigh University with a degree in electrical engineering and received an MBA from the University of Delaware.
Leadership

L. Jay Katz, MD
Director, Glaucoma Service,
Wills Eye Hospital
Professor of Ophthalmology,
Jefferson Medical College

Dr. Katz has wide-ranging interests in glaucoma, including drug evaluation, laser and medical management in glaucoma treatment, optic nerve scanning methodologies, and glaucoma surgical techniques.

He is on the advisory boards of pharmaceutical and glaucoma device companies, including Glaukos, Bausch + Lomb, Allergan, Aerie, and Merck.

Dr. Katz received his BA from Case Western Reserve University and his MD from Yale University School of Medicine. He completed his ophthalmology residency at Yale and then moved to Wills Eye Hospital for his glaucoma subspecialty training.

Ruth D. Williams, MD
President,
Wheaton Eye Clinic
Board of Directors,
Glaucoma Research Foundation

Dr. Williams is the President of the Wheaton Eye Clinic, a 74-year-old ophthalmology practice that provides subspecialty eye care to more than 140,000 patients annually.

She is a past president of the American Academy of Ophthalmology, representing ophthalmology at the AMA for nearly a decade and chairing its specialty section.

After attending Rush Medical College, Dr. Williams completed an ophthalmology residency at California Pacific Medical Center in San Francisco and a glaucoma fellowship at Shaffer Associates and the University of California San Francisco.

Opening Keynote Address
Drs. Henry and Frederick Sutro Memorial Lecture

Richard A. Lewis, MD
Co-founder, Sacramento Eye Consultants
Former Director of Glaucoma, University of California, Davis
Past President, American Society of Cataract and Refractive Surgery
Past President, American Glaucoma Society

Dr. Lewis is the former director of glaucoma at the University of California, Davis. In addition to his clinical practice, he is involved in clinical research trials in anterior segment disease and glaucoma therapy. He previously served as President of both the ASCRS and the AGS. Dr. Lewis is the medical Editor Emeritus of *Glaucoma Today* and on the editorial board of the *Journal of Cataract and Refractive Surgery*, *Journal of Glaucoma*, and *Ocular Surgery News*. He is co-founder of Sacramento’s Capital City Surgery Center.

Dr. Lewis attended the University of California, Berkeley and received his doctorate in medicine from Northwestern University Medical School. He completed his residency at the University of California, Davis, and a fellowship at the University of Iowa. He is a Diplomat of the American Board of Ophthalmology and the National Board of Medical Examiners.

He has published over 90 articles and book chapters focusing on glaucoma, ophthalmic surgery, and pharmacology. He has received the American Academy of Ophthalmology Honor and Senior Honor as well as the Secretariat and Life Achievement Awards for his contributions in teaching and leadership and for initiating the AAO Subspecialty Day meeting.
DEDICATED
to changing the Glaucoma landscape

We believe everyone should have the best possible vision throughout their lives.

As the leader in eye care, Alcon is dedicated to changing the glaucoma landscape through a focus on science, innovation and leadership, and by developing a glaucoma portfolio designed to address unmet patient needs at all stages of the disease.

We are committed to long-term investments in research and development in order to advance the treatment of patients living with glaucoma and reduce the burden of disease around the world.
Dr. Aref is Assistant Professor of Ophthalmology, Associate Residency Program Director, and Chief Quality Officer at the Illinois Eye & Ear Infirmary, University of Illinois at Chicago. He is an active clinician specializing in cataract, glaucoma, and anterior segment procedures. Dr. Aref completed his medical training at Northwestern University and subsequently performed ophthalmology residency at the Penn State Hershey Eye Center. He completed his glaucoma fellowship at The Bascom Palmer Eye Institute in Miami, Florida. Dr. Aref is board-certified by the American Board of Ophthalmology as well as the Royal College of Physicians & Surgeons of Canada.

Mr. Abelson has been a Director at Ora—a leading independent ophthalmic drug and device development firm—since 1995 and has served as the company’s Chairman from 1997 until his appointment as President in 2007.

Prior to joining Ora, Mr. Abelson served in various positions, including most recently Director of Technical Business Development at Amphenol, one of the largest manufacturers of interconnect products in the world. From 1999 through 2005, he served as General Manager of Amphenol’s fiber optic product division.

Mr. Abelson graduated Phi Beta Kappa and Magna Cum Laude with a BS degree in neuroscience from Bates College where he was a Charles A. Dana Scholar. He holds an MBA from Northwestern University’s Kellogg School of Management.

Anthony P. Adamis, MD
Senior Vice President and Global Head of Ophthalmology, Immunology, Infectious Diseases and Metabolism, Clinical Science Genentech, Inc.

Anthony P. Adamis, MD is Senior Vice President and Global Head of Ophthalmology, Immunology, Infectious Disease & Metabolism, Clinical Science at Genentech. Dr. Adamis is best known for his co-discovery of the role of VEGF in ocular disease. Previously, he co-founded Eyetech and Jerini Ophthalmic. Dr. Adamis was on the full time faculty of the Harvard Medical School and was co-director of the Ocular Angiogenesis Laboratory at the Massachusetts Eye and Ear Infirmary from 1991-2002. His research is focused on AMD, diabetic retinopathy, and ocular drug delivery. He received his MD with Honors from the University of Chicago, completed his residency at the University of Michigan, and fellowship at Massachusetts Eye and Ear Infirmary.

Eddy Anglade, MD
Chief Medical Officer
Ocata Therapeutics

Dr. Eddy Anglade joined the company in 2014 as the Company’s Executive Vice President of Clinical Development. Previously Dr. Anglade was Chief Medical Officer and Co-founder of Lux Biosciences, Inc., a privately held development stage biotechnology company. As Chief Medical Officer at Lux, his responsibilities included leadership of clinical development, regulatory strategy and safety for all of its clinical programs. He started his career in the pharmaceutical industry at Hoffmann-LaRoche, Inc.

Dr. Anglade completed his ophthalmology residency at the Massachusetts Eye and Ear Infirmary/Harvard Medical School with specialty training at the National Eye Institute/National Institutes of Health and received his MD from Yale University School of Medicine.

Ahmad A. Aref, MD
Professor of Ophthalmology
University of Illinois, Chicago
New World Medical

Lawrence Benowitz, PhD
Director,
Laboratories for Neuroscience Research in Neurosurgery
Boston Children’s Hospital
Professor of Neurosurgery and Ophthalmology
Harvard Medical School

Dr. Benowitz is the Director of the Labs for Neuroscience Research in Neurosurgery at Boston Children’s Hospital and a Professor of Neurosurgery and Ophthalmology at Harvard Medical School. He received his PhD from Caltech and did postdoctoral work at MIT and Harvard.

His laboratory studies axon growth and the rewiring of neural connections after CNS injury, with a major focus on identifying factors that regulate retinal ganglion cell survival and axon regeneration after optic nerve injury. He was named as one of Scientific American’s 50 leaders in 2006 and received the Lewis Rudin Glaucoma Prize in 2013/14.

Dr. Berdahl specializes in Refractive, Cataract, Corneal and Glaucoma Surgery. He graduated from Mayo Medical School and completed an internship at the Mayo Clinic Scottsdale, residency at Duke University and a fellowship at Minnesota Eye Consultants. He has won numerous national awards including Harvard University’s Claes Dohlman Award, the Resident Writers Award, and was recently named in the Top 40 under 40 ophthalmologists worldwide.

He serves on the Vision for Mars program and started a device company to treat diseases caused by an imbalance between...
Dr. Blumenkranz has published numerous peer-reviewed articles. His research interests include cerebrospinal fluid pressure in glaucoma, MIGS, ReLACS, and intraocular lens design. He holds a leadership role in EyeCare America and has completed surgical mission trips worldwide.

Kapil Bharti, PhD
Stadtman Investigator
Unit of Ocular Stem Cell & Translational Research
National Eye Institute

Dr. Bharti obtained his PhD from Goethe University, Frankfurt, Germany, graduating *summa cum laude*. His PhD work involved research in the areas of molecular chaperones and epigenetics. He did his postdoc at the NIH, where he published numerous papers in the areas of transcription regulation, pigment cell biology, and ocular developmental biology. He has won several awards, including, most recently, being selected as an Earl Stadtman Tenure-Track Investigator at NIH and receiving a Therapeutic Challenge Award from NIH Common Fund to develop a phase 1 IND for autologous iPS cell derived retinal pigment epithelium based cell therapy.

Mark S. Blumenkranz, MD, MMS
H.J. Smead Professor of Ophthalmology
Department of Ophthalmology
Stanford University

Dr. Blumenkranz is HJ Smead Professor in the Department of Ophthalmology at Stanford University. He received his undergraduate, graduate degree, and medical education at Brown University as well as the Graduate School of Business at Stanford. He completed his internship in surgery and ophthalmic residency training at Stanford and a fellowship at the Bascom Palmer Eye Institute. He served as Chairman of the Department of Ophthalmology at Stanford and the Founding Director of the Byers Eye Institute at Stanford until 2015.

Dr. Blumenkranz has a longstanding interest and expertise in university corporate technology transfer and early stage biomedical company development having either founded or served on the Boards of Directors of a number of successful medical drug and device companies.

James D. Brandt, MD
Professor of Ophthalmology and Vision Science
Director of Glaucoma Service
University of California, Davis

Dr. Brandt received his BS from Yale University and an MD from Harvard Medical School, then pursued a two-year post-doctoral research fellowship at the Schepens Eye Research Institute before his residency at the Doheny Eye Institute.

Dr. Brandt’s clinical practice is limited to glaucoma, with a particular focus on infantile and pediatric. His research interests are in the material properties of the eye as they affect the measurement of intraocular pressure and the physiology of outflow resistance. He is currently collaborating with researchers in the fields of nanotechnology, micro-fabrication and biomedical engineering to develop new methods to measure outflow resistance in the living human eye. He has served as the Principal Investigator of numerous clinical trials.

Wiley Chambers, MD
Supervisory Medical Officer
Division of Transplant and Ophthalmology Products
FDA

Dr. Chambers is a Clinical Professor of Ophthalmology and Adjunct Assistant Professor of Computer Medicine at The George Washington University.

He joined the FDA in 1987 as a primary reviewer for ophthalmic drug products. In 1990 he became a Supervisory Medical Officer for
EARLY GLAUCOMA

ABiC

Performed via a self-sealing clear corneal incision, ABiC™ is a new ab-interno MIGS procedure that flushes out the natural outflow channels, without damaging tissue and without leaving behind a stent or shunt.

EARLY-MILD GLAUCOMA

SLT

Whether used as primary, adjunct or replacement therapy, SLT lowers IOP as effectively as medication, has a consistent safety profile, and best of all, it works 24 hours a day, 7 days a week, to keep IOP under control.

MILD-ADVANCED GLAUCOMA

CANALOPLASTY

A restorative glaucoma surgery, Canaloplasty comprehensively opens up all components of the eye’s natural outflow system to provide long-term reduction in IOP and medication burden.
Speakers, Moderators and Panelists

Jeffrey L. Cleland, PhD
Interim Chief Executive Officer
GrayBug

Dr. Cleland has 25 years of industry experience in research and development. He has played major roles in obtaining more than $450 million in capital including over $300 million in capital raised as CEO of Versartis (VSAR), where he led one of top biotech IPOs of all time. He has managed directly all aspects of pharmaceutical development and late-stage research. While at Genentech, he held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as early work on Lucentis®, Avastin®, Omnitarg® and Kadcyla®. He holds a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and 4 books, and holds several issued patents.

Alan S. Crandall, MD
President, Professor of Ophthalmology and Visual Services, Senior Vice Chair, Director of Glaucoma and Cataract Co-Director, Division of International Ophthalmology, John A. Moran Eye Center University of Utah

Dr. Crandall is a member of the American Society of Cataract and Refractive Surgery, American Glaucoma Society, the European Society of Cataract and Refractive Surgeons, as well as the International Intra-Ocular Implant Club.

He graduated from the University of Utah, receiving his medical degree from the University of Utah School of Medicine. Dr. Crandall completed his internship in surgery at the University of Pennsylvania Medical Center as well as his residency and fellowship in ophthalmology at the Scheie Eye Institute, University of Pennsylvania. He joined the University of Utah Ophthalmology Department in 1981.

Emmett Cunningham, Jr., MD, PhD, MPH
Partner
Clarus Ventures

Dr. Cunningham joined Clarus Ventures in 2006 with more than 20-years’ experience in the biomedical and biopharmaceutical sectors. He also founded and serves as Chairman of the Ophthalmology Innovation Summit (OIS).
Gina Dellacqua is the Vice President of the Specialty Diagnostics Division at Haag-Streit-USA located in Mason, Ohio. For over 150 years, Haag-Streit has been a leading provider of medical equipment for ophthalmologists, optometrists, and opticians. Haag-Streit sets the standard for precision mechanics and innovative technology with an emphasis on usability and functionality. As part of the Specialty Diagnostics Division, her leadership is key to continue the longevity and accelerate the broad-market success distribution of the finest precision medical instruments on the market today. Dellacqua started her professional career in optometry/ophthalmology specializing in glaucoma/retinal diseases in 1992. She then joined Zeiss, specializing in all ophthalmic medical devices for 8 years. She joined Haag-Streit-USA in 2014.

Dr. de Juan serves as Vice-Chairman of ForSight Labs and is the Jean Kelly Stock Distinguished Professor in Ophthalmology at UCSF. He has participated in the development of a number of new technologies with over 100 products including the “retina chip,” minimally invasive retinal surgery, ocular drug delivery and the founding of nine venture-funded companies. He has previously served as Professor of Ophthalmology at the University of Southern California and CEO at the Doheny Retina Institute, Co-Director of Vitreoretinal Service at the Wilmer Eye Institute at Johns Hopkins University School of Medicine, Director of the Microsurgery Advanced Design Laboratory, and Joseph E. Green Professor of Ophthalmology. He completed his medical degree and internship training at the University of South Alabama College of Medicine.

Dr. Eydelman is a board-certified ophthalmologist. She received her undergraduate degree in Electrical Engineering from Cooper Union for the Advancement of Science and Art. She received her MD degree from Harvard Medical School and a Doctorate in Health Sciences and Technology from Massachusetts Institute of Technology. In 1995, Dr. Eydelman joined the FDA. For the past 20 years, as an Expert Medical Officer, Senior Medical Advisor, and Director of FDA’s Division of Ophthalmic, Neurological and Ear, Nose and Throat Devices, she has played a key role in assuring the safety and effectiveness of ophthalmic medical devices. She has been involved in standardization of ophthalmic devices as the U.S. Expert Delegate to the International Standards Organization and FDA’s Liaison to the American National Standards Institute’s Committee for Ophthalmic Devices.

Dr. Cunningham received his MD and MPH from Johns Hopkins University, his PhD from the University of California, San Diego, and completed his residency and fellowship at UCSF. He completed additional fellowships at Moorfields Eye Hospital in London and the Wilmer Eye Institute.

Dr. Fechtner chairs the Institutional Review Board for human subject research at the New Jersey Medical School in Newark. He is also the Executive Vice President of the World Glaucoma Association. Dr. Fechtner is a highly regarded glaucoma educator. He has organized major glaucoma symposia for the American Academy of Ophthalmology, American Society of Cataract and Refractive Surgeons, the World Glaucoma Congress and the American Glaucoma Society. He has published over 100 articles, book chapters and monographs and is the associate editor of the Textbook of Ocular Pharmacology. He has served on the editorial boards of American Journal of Ophthalmology, Journal of Glaucoma, Review of Ophthalmology, and Video Journal of Ophthalmology.

Yehia Hashad is a physician and business leader with degrees in ophthalmology and business. He has more than 18 years of experience in the international arena with leading multinational pharmaceutical companies in the field of clinical drug development and management. His experiences in the industry have given him substantial exposure and knowledge of market dynamics, policies, and politics in particular related to drug development. He is experienced in
UNITING OVER 400 LEADERS
IN THE DEVELOPMENT OF GROUND-BREAKING
OPHTHALMIC TECHNOLOGIES

The Ophthalmology Innovation Summit was created to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation. OIS addresses key issues – both hurdles and opportunities while showcasing the most innovative ophthalmic companies.

WWW.OIS.NET
establishing and retaining clinical/regulatory teams, designing clinical development programs, working with worldwide health authorities, exploring new indications and opportunities for products, and worldwide clinical support of new products. He is responsible at Allergan for creating worldwide therapeutic area strategies, as well as design and oversight of all clinical development programs in ophthalmology therapeutic areas.

Ms. Hutton is a seasoned healthcare investor, passionate about investing in and building companies that are revolutionizing the practice of medicine. She has facilitated bringing over a dozen medical devices and drugs to market. Prior investments include BiPar Sciences, Chimerix, and Labrys Biologics. She joined Canaan Partners in 2004 and her life sciences track record includes seven IPOs and five acquisitions. She was honored as one of The Most Influential Women in Bay Area Business 2015 by The San Francisco Business Times.

Ms. Hutton holds a BA from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar.

In 2012, Nir co-founded Sanoculis, which offers an alternative new surgical technique Minimally Invasive Micro Sclerostomy (MIMS™) surgery for Glaucoma treatment. MIMS™ is based on the adaptation of well-known procedures and utilization of specially developed equipment and technology.

In parallel, he co-founded EyeOP which developed a new gold-standard-based method for Intraocular Pressure (IOP) measurement in the lying down position. The method considerably improves the diagnostic ability and management of Glaucoma treatment.

Mr. Israeli holds an MBA in Marketing and Financing from the Recanati Business School, Tel Aviv University, and a BSc. in Computer Engineering from the Technion, Israel Institute of Technology.

Dr. Jasek is currently Vice President of Medical and Scientific Affairs for Ophthalmics and Neurologics at Sun Pharma. He has spent the last 18 years in the pharmaceutical, biologics, medical device and diagnostic spaces across multiple therapeutic disciplines. His experience spans from bench to commercialization, with responsibilities in Clinical Development, Pharmacokinetics, Global Medical Affairs, Global Sales Training, Advocacy Development, Marketing, Business Development, and Executive Leadership. Dr. Jasek was a postdoctoral scholar at California Institute of Technology and holds a PhD from Texas A&M University Health Science Center in Medical Sciences with a focus on neuropharmacology.

Dr. Johnson was named CMO of Neurotech in March of 2015. Dr. Johnson was most recently the Vice President of Global Medical Affairs at Vertex. Prior to this, he held leadership positions at Inspire Pharmaceuticals and APT Pharmaceuticals. During his 13 year tenure at Genentech, he lead the Immunology and Tissue Repair clinical group with responsibility for the approvals of LUCENTIS® for wet age-related macular degeneration, RITUXAN® for rheumatoid arthritis and XOLAIR® for severe allergic asthma. Dr. Johnson received his medical degree from the University of Cape Town in South Africa, attained Board Certification in Pediatrics at the Red Cross War Memorial Children’s Hospital. He spent six years at Washington University in Saint Louis before joining industry.

Dr. Kahook is Professor of Ophthalmology and The Slater Family Endowed Chair in Ophthalmology at the University of Colorado School Of Medicine. He is Vice Chair of Clinical and Translational Research and is chief of the glaucoma service and director of the glaucoma fellowship at the University of Colorado Eye Center. Dr. Kahook authored over 300 peer-reviewed manuscripts, abstracts, and book chapters. He was named New Inventor of the Year for the University of Colorado in 2009 and Inventor of the Year in 2010. Dr. Kahook has also received numerous awards and filed for over 30 patents with 20 licensed by companies for development. Four of his devices are currently in human trials or available globally for clinical use. He serves on several editorial boards and is a consultant to the FDA’s Ophthalmic Device Division.

Dr. Katz has wide-ranging interests in glaucoma, including drug evaluation, laser and medical management in glaucoma treatment, optic nerve scanning methodologies, and glaucoma surgical techniques.
Speakers, Moderators and Panelists

Bilal Khan
Vice-President and Chief Operating Officer
New World Medical

Mr. Khan is Vice President and Chief Operating Officer of New World Medical (NWM), a medical device firm based in Rancho Cucamonga, California. He also serves on the Boards of Directors of Oculogica, a neurodiagnostic start-up. Prior to joining NWM, he worked as an Actuary in Chicago, Los Angeles, and London, becoming a Fellow of the Society of Actuaries in 2008. Mr. Khan holds a Bachelor of Business Administration in Actuarial Science from the University of Wisconsin-Madison, and a Master of Business Administration in Management from The Wharton School of the University of Pennsylvania, where he graduated with honors.

Gilbert Kliman, MD
Managing Director
InterWest Partners

Dr. Kliman joined InterWest’s life sciences team in 1996 and leads the firm’s investments in medical devices and digital health. He invests in a broad array of life sciences opportunities with a special interest in ophthalmology. He has been a lead investor and board member at Avedro, Benvenue Medical, Epocrates (EPOC), Glaukos (GKOS), IntraLase (ILSE), LenSx Lasers, Restoration Robotics, and ReVision Optics. Dr. Kliman has a BA from Harvard University. He received an MD from the University of Pennsylvania and an MBA from Stanford University. He completed ophthalmology residency at Wills Eye Hospital and a retina laser fellowship at Massachusetts Eye and Ear Infirmary. He serves as a National Trustee of the Foundation Fighting Blindness.

Ralf Kuschnereit, PhD
President and Chief Executive Officer
Carl Zeiss Meditec, Inc.

Dr. Kuschnereit has been President and CEO of Carl Zeiss Meditec, Inc. since January 2010 where he oversees U.S. operations for the global CZ Meditec organization. Prior to his appointment, Dr. Kuschnereit was Executive Vice President of Business Sectors and Innovation.
Eliot Lazar, MD
President
elCON Enterprises, Inc.

eCON is a consulting firm that provides an end-user medical and surgical perspective on the medical device market’s needs and requirements, medical technology trends and developments, and funding strategies with a strong focus on ophthalmology therapeutics, both devices and pharmaceuticals. eCON has provided strategic guidance to companies at all stages in order to move them forward. eCON also provides support to a broad swath of the Investment community.

An ophthalmologist specializing in anterior segment pathology and surgery, Dr. Lazar has several university appointments, holds patents on ophthalmic drug delivery, has published numerous articles and collaborates with both the device and the pharmaceutical industry in order to translate technologies into clinical relevance. He collaborates with leaders across the industry.

eCON also effectively translates technologies into a utilitarian pathway and has effectively guided organizations to successful endpoints.

Richard L. Lindstrom, MD
Founder
Minnesota Eye Consultants, PA

Dr. Lindstrom, founder and attending surgeon at Minnesota Eye Consultants, Adjunct Clinical Professor Emeritus at the University of Minnesota Department of Ophthalmology, Associate Director: Minnesota Lions Eye Bank, Board Member: University of Minnesota Foundation, and visiting Professor: UC Irvine, Gavin Herbert Eye Institute.

Dr. Lindstrom is a board-certified ophthalmologist and internationally recognized leader in corneal, cataract, refractive and laser surgery. He has been at the forefront of ophthalmology’s evolutionary changes throughout his career, as a recognized researcher, teacher, inventor, writer, lecturer and highly acclaimed physician and surgeon.

Dr. Lindstrom holds over 38 patents in ophthalmology and has developed a number of solutions, intraocular lenses and instruments that are used in clinical practices globally.

K. Angela MacFarlane, JD
President and Chief Executive Officer
ForSight Labs

ForSight Labs is a company focused on creating a community where innovation and practical application of ideas are combined to create companies focused on improving the lives of visually impaired patients. Since 2005, ForSight has started six companies focused on key needs in ophthalmology such as treatment of glaucoma and macular degeneration.

Prior to joining ForSight Labs, Ms. Macfarlane served as Chief Technology Counsel to The Foundry and as Technology Counsel for Thomas J. Fogarty, MD, where she participated in all aspects of early stage technology review, licensing, intellectual property management and company creation.

Ms. MacFarlane received her BA in Business Administration from San Francisco State University, and her JD from Golden Gate University School of Law.

Cynthia Mattox, MD, FACS
Director of the Glaucoma and Cataract Service,
New England Eye Center
Associate Professor and Vice-Chair,
Department of Ophthalmology
Tufts University School of Medicine

Dr. Mattox has been a member of the AAO Health Policy Committee since 2004 and begins her term as Trustee-at-Large for the AAO Board of Trustees in 2016. She is involved in the development of the IRIS Clinical Registry and chairs the Measure Development Taskforce. She has served on the American Glaucoma Society (AGS) Board since 2008. She currently serves as the Vice-President/President. Locally she is on the New England Ophthalmological Society’s Ophthalmic Services committee.

Along with her busy practice, Dr. Mattox trains fellows and residents in glaucoma and cataract management and surgery, receiving the Resident Teaching Award three times. National awards include the 2014 Outstanding Advocate Award, the AAO’s Secretariat Award and Senior Achievement Award, and the AGS’s President’s Award.

Thomas Mitro
President and Chief Operating Officer
Aerie Pharmaceuticals, Inc.

Mr. Mitro has over 30 years of pharmaceutical industry experience in sales and marketing, commercial operations, and business development. Prior to joining Aerie, he most recently served as Vice President, Sales and Marketing at Omeros Corporation, a publicly traded clinical-stage biopharmaceutical company.

Before this, he was Vice President, Sales and Marketing at ISTA Pharmaceuticals, where he was instrumental in building commercial operations and launching several eye care products. At the time of
what we do at Ora

Variability
Sensitivity
& Precision
Probability of Success
Total Development
Cost & timelines
ROI

Ora is the world’s leading independent, full-service ophthalmic CRO and product development firm with offices in the United States and Japan. Over the past 30 years, we helped our clients earn 40 FDA approvals. We support a wide array of organizations, from start-ups to global pharmaceutical and device companies, to efficiently and successfully bring their new products from concept to market. Ora’s pre-clinical and clinical models, unique methodologies and regulatory strategies have been refined and proven across thousands of projects both in the US and internationally. We bring together the world’s most extensive and experienced network of ophthalmic experts and R&D professionals to maximize the value of new product initiatives.

(978) 494-4899
www.oraclinical.com
ISTA’s acquisition by Bausch + Lomb, ISTA had grown to become the third largest branded prescription eye care business in the U.S. Previously, he held various positions at Allergan, Inc., including Vice President, Skin Care; Vice President, Business Development; and Vice President, e-Business. He received his BS degree from Miami University.

Aziz Mottiwala, Allergan’s Vice President of US Eyecare Marketing, is a 15+ year healthcare veteran, with nearly a decade of experience specifically in Eyecare. In his current role he leads the marketing efforts, strategy, and promotion of Allergan’s eyecare products in Dry Eye, Glaucoma, and OTC Tears. His experience spans a broad range of commercial responsibilities, in numerous therapeutic areas. His expertise has contributed to strategies for both in-line and development products, as well as licensing and acquisition projects. He holds a BS in Biochemistry from UC San Diego, and an MBA from the Marshall School of Business at the University of Southern California.

Gary D. Novack, PhD
President
PharmaLogic Development, Inc.
Visiting Professor of Pharmacology and Ophthalmology, University of California Davis, School of Medicine

Dr. Novack is the founder and president of PharmaLogic Development, Inc.—a consultancy providing development expertise to pharmaceutical and medical device companies specializing in ophthalmology and other local therapies. He has played a key role in the approval of over 40 ophthalmic products. He is a member of many professional societies, including the Glaucoma Research Society, and has served in leadership roles in the American society of clinical Pharmacology and Therapeutics. Dr. Novack received his BA from the University of California Santa Cruz, his PhD in Pharmacology and Toxicology from the University of California Davis, and his postdoctoral fellowship in neurophysiology at the University of California Los Angeles. He earned his diploma in clinical pharmacology in 1990, the inaugural year of the certification.

Chris Pulling
Chief Executive Officer
MicroOptx

Mr. Pulling is CEO of MicroOptx, a MedTech company developing a novel treatment for glaucoma. Prior to MicroOptx, Chris was CEO of The Integra Group, a contract research organization he founded in 2002. He led Integra from formation through acquisition by the world’s largest medical device CRO. At Integra, Chris and his staff supported over 400 medical device companies, and he was integrally involved in over 30 PMA approvals and 10 FDA advisory panels. Previous management experience also includes Medtronic. Chris has an MS in Biostatistics from the University of Minnesota and a BA in Mathematics from Hamline University.

David E.I. Pyott, CBE
Former Chairman of the Board and Chief Executive Officer, 1998–2015
Allergan, Inc.

During his 17 year tenure, Allergan was transformed from a small business with about $1 billion in sales to a global specialty pharmaceutical and medical device company, with sales over $7 billion in 2014. Allergan’s market capitalization increased from $2.3 billion in 1998 to $72 billion when it was acquired by Actavis in 2015. Mr. Pyott was recognized by Harvard Business Review as one of “The 100 Best Performing CEOs in the World” in 2014. In 2006, Mr. Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen. Mr. Pyott is Lead Director and a member of the Board of Directors of Avery Dennison Corporation and the Supervisory Board of Royal Philips in the Netherlands. He is a Governor of London Business School and Vice Chairman of the Board of Trustees of Chapman University.

Cadmus C. Rich, MD, MBA, CPE
Vice President, Medical Affairs and Clinical Development
Inotek Pharmaceuticals

Dr. Rich joined Inotek Pharmaceuticals in 2015 as Vice President of Medical Affairs and Clinical Development. Prior to Inotek, Dr. Rich was with Alcon and before joining Alcon, he was with Quintiles Transnational. Dr. Rich earned his bachelor’s degree from Case Western Reserve University, his MD from the UNC School of Medicine, his Ophthalmology training at UNC Hospitals, his MBA from Regis University and his CPE from the American Association for Physician Leadership. He has 20 years of experience in clinical medicine and in R&D developing both drugs and devices. He has contributed or led over 25 product development programs, 100 clinical trials in multiple indications in ophthalmology and other therapeutics areas.

Bernhard A. Sabel, PhD
Director
Institute of Medical Psychology
Otto-von-Guericke University of Magdeburg

Bernhard A. Sabel, PhD is Professor of Medical Psychology, Magdeburg University (Germany) and at China’s leading eye clinic (Beijing Tongren Hospital). He is Editor of Restorative Neurology and Neuroscience and has pioneered the field of vision restoration after visual nervous system damage. He is founder of start-ups in glaucoma, optic neuropathy and hemianopia using training and non-invasive brain stimulation to modulate brain plasticity through functional brain network reorganization. He received his PhD at Clark University (Worcester, MA) and was post-doc at MIT, subsequently working at University of Munich (Germany), Harvard Medical School, Princeton University and the Chinese Academy of Sciences.
Speakers, Moderators and Panelists

Amar Sawhney, PhD
President, Chief Executive Officer
Chairman, Board of Directors
Ocular Therapeutix, Inc.

Amar Sawhney, PhD, is the President, CEO and founder of Ocular Therapeutix, a biopharmaceutical company focused on the development and commercialization of sustained therapies for diseases and conditions of the eye. Dr. Sawhney was previously the founder and CEO of Confluent Surgical (acquired by Covidien), the Chairman of MarketRx (acquired by Cognizant) and technology founder of Focal, Inc. (acquired by Genzyme) and Access Closure, Inc. (acquired by Cardinal Health). Dr. Sawhney’s innovations are the subject of over 100 issued and pending patents. Dr. Sawhney holds a PhD and MS in Chemical Engineering from the University of Texas at Austin and a B.Tech. in Chemical Engineering from IIT Delhi.

Christy Shaffer, PhD
Partner
Hatteras Ventures

Seasoned entrepreneur and executive, Christy Shaffer, PhD has over 25 years of experience in the life science industry. Following her career as a clinical scientist, international project leader and Associate Director of Pulmonary and Critical Care Medicine at Burroughs Wellcome Co., she joined Inspire Pharmaceuticals. As President and Chief Executive Officer, Dr. Shaffer grew the company from 20 to nearly 250 employees with revenues of over $100m. Dr. Shaffer serves as a board member of five Hatteras portfolio companies and chairs three of them: Clearside (Chair), KinoDyn (Chair), and GrayBug (Executive Chair). She is a receptor pharmacologist by training, earning her PhD in Pharmacology from the University of Tennessee Health Science Center. She received her post-doctoral training at The Chicago Medical School and the University of North Carolina at Chapel Hill.

Paul Schacknow, MD, PhD
Consultant in Glaucoma
East Florida Eye Institute
Clinical Associate Professor
Division of Ophthalmology
Nova Southeastern University

Dr. Schacknow earned his PhD in auditory and visual psychophysics at the City University of New York. His medical training was from the unique, accelerated, curriculum of the PhD to MD Program at the University of Miami, where he received the Doctor of Medicine degree in 1983 after 23 months. He followed his internship at Framingham-Union Hospital in Massachusetts, with an ophthalmology residency at Massachusetts Eye and Ear Infirmary, and a fellowship in glaucoma management at California Pacific Medical Center. He was President of the Palm Beach County Ophthalmology Society in 2001. Most recently he has co-edited two major textbooks, The Glaucoma Book (2010) and Clinical Glaucoma Care (2013).

Kuldev Singh, MD, MPH
Professor of Ophthalmology
Director of Glaucoma Service
Stanford University School of Medicine

Dr. Singh has served as President of the American Glaucoma Society and Executive Vice President of the World Glaucoma Association. He is presently a Standing Member on the Medical Devices Advisory Committee of the U.S. Food and Drug Administration. Dr. Singh received his MD and MPH degrees from the Johns Hopkins University School of Medicine and was an Eleanor Naylor Dana Charitable Trust Fellow at the Wilmer Eye Institute. He completed his ophthalmology residency at the Casey Eye Institute, Oregon Health and Science University followed by a Heed Foundation Fellowship focusing on glaucoma at the Bascom Palmer Eye Institute.

Russ Trenary
President and Chief Executive Officer
InnFocus, Inc.

Russ Trenary is President and Chief Executive Officer for InnFocus, Inc., an early stage company pioneering microsurgical solutions for glaucoma. He has led, or been a named officer, in medical device companies for over 20 years, and has raised over $80MM of capital. His managerial experience includes specific interfacing in marketing, sales, finance, R&D, regulatory, and manufacturing. He has turned unprofitable $100M divisions at Allergan (NYSE:AGN) into highly profitable entities, and also significantly increased profitability in $500MM divisions at AMO (NYSE:EYE). He also has vast experience with large volume product launch and acquisitions like Pharmacia Surgical, Ioptex, VISX, Intralase, and Optical Micro Systems.

Vivek J. Srinivasan, PhD
Assistant Professor of Biomedical Engineering
University of California, Davis

Dr. Srinivasan is currently Assistant Professor of Biomedical Engineering (primary) and Ophthalmology (secondary) at the University of California Davis. He leads a diverse but integrated research program that develops and applies novel imaging techniques to understand neuronal and metabolic control of hemodynamics in the central nervous system, and has been funded in these efforts by the National Institutes of Health and American Heart Association. He has an extensive background in biomedical optics and photonics, and has made contributions to retinal and optic nerve head imaging technologies that are currently used in the clinic. His laboratory is part of the Glaucoma Research Foundation Catalyst for a Cure Biomarker Initiative.

Stanford University School of Medicine
Director of Glaucoma Service
Professor of Ophthalmology
Kuldev Singh, MD, MPH

Vivek J. Srinivasan, PhD
Assistant Professor of Biomedical Engineering
University of California, Davis

Dr. Singh has served as President of the American Glaucoma Society and Executive Vice President of the World Glaucoma Association. He is presently a Standing Member on the Medical Devices Advisory Committee of the U.S. Food and Drug Administration. Dr. Singh received his MD and MPH degrees from the Johns Hopkins University School of Medicine and was an Eleanor Naylor Dana Charitable Trust Fellow at the Wilmer Eye Institute. He completed his ophthalmology residency at the Casey Eye Institute, Oregon Health and Science University followed by a Heed Foundation Fellowship focusing on glaucoma at the Bascom Palmer Eye Institute.

Russ Trenary
President and Chief Executive Officer
InnFocus, Inc.

Russ Trenary is President and Chief Executive Officer for InnFocus, Inc., an early stage company pioneering microsurgical solutions for glaucoma. He has led, or been a named officer, in medical device companies for over 20 years, and has raised over $80MM of capital. His managerial experience includes specific interfacing in marketing, sales, finance, R&D, regulatory, and manufacturing. He has turned unprofitable $100M divisions at Allergan (NYSE:AGN) into highly profitable entities, and also significantly increased profitability in $500MM divisions at AMO (NYSE:EYE). He also has vast experience with large volume product launch and acquisitions like Pharmacia Surgical, Ioptex, VISX, Intralase, and Optical Micro Systems.
Ms. Valorie is the Senior Vice President and General Manager of Ophthalmology Rx of Bausch + Lomb Pharmaceuticals and previously served as the Global Head of Glaucoma. Prior to joining B+L, Ms. Valorie was Pfizer’s Commercial Lead of Ophthalmology where she was responsible for marketed products, mid-stage development portfolio, and long range planning.

Her 20+ year career has included roles in discovery science, clinical development, early commercial assessment, marketing, and strategic planning.

Ms. Valorie has held board membership seats at The Glaucoma Foundation and the ARVO foundation for Eye Research.

Dr. Vold founded Vold Vision after previously serving as Vice Chairman of the Department of Ophthalmology and Director, Division of Glaucoma at the Scott and White Eye Institute and Texas A&M College of Medicine in Temple, Texas.

He has been listed in the Consumer’s Research Council of America’s Guide to America’s Top Ophthalmologists every year since 2002. He currently serves as Chief Medical Editor of Glaucoma Today, and co-founded the American-European Congress of Ophthalmic Surgery.

Dr. Vold also co-founded the Silicon Valley-based ophthalmic device company Ocunetics, Inc. whose intellectual property was exclusively licensed by IRIDEX Corporation in 2011.

Dr. Williams is CEO of the Wheaton Eye Clinic, a 73-year-old ophthalmology practice that provides subspecialty eye care to more than 140,000 patients annually.

She is a past president of the American Academy of Ophthalmology, representing ophthalmology at the AMA for nearly a decade and chairing its specialty section.

After attending Rush Medical College, Dr. Williams completed an ophthalmology residency at California Pacific Medical Center in San Francisco and a glaucoma fellowship at Shaffer Associates and the University of California San Francisco.

Dr. Yerxa is a co-founder of Envisia Therapeutics, an ophthalmic drug delivery company spun out of Liquidia Technologies. Previously, he was Vice President of Research and Development at Clearside Biomedical and the Executive Vice President and Chief of Research & Development at Inspire Pharmaceuticals, a top-ranked publicly-traded biotech company acquired by Merck & Co., Inc. During his time at Inspire, Dr. Yerxa helped the company build and commercialize a portfolio of innovative new products.

Throughout his 20-year career in the pharmaceutical and biotechnology industry, Dr. Yerxa has been involved with the discovery and development of several investigational new drugs (INDs), phase 3 clinical programs, new drug applications (NDAs), and drug approvals.

His experience spans a variety of therapeutic areas including ophthalmology, pulmonary, cardiovascular, and HIV.
A dedicated team focused solely on eye care professionals. 
An innovative pipeline designed to improve the way you treat. 
A shared passion for advancing the field of ophthalmics. 

With our unique approach and concierge customer care, Sun Ophthalmics offers the promise of new beginnings in the ophthalmic landscape. 

Founded in 1978 in San Francisco, Glaucoma Research Foundation was created to encourage innovative research to find better ways to care for people with glaucoma and ultimately find a cure.

Our Commitment to Education and Awareness
Glaucoma Research Foundation remains a principal source of information and support for doctors, patients and their families. We distribute more than 100,000 issues of our Gleams newsletter three times a year through the mail, by doctors’ offices and by email. Our website, www.glaucoma.org, helps over 3 million visitors annually with useful and accurate information. Both our website and our educational booklet "Understanding and Living with Glaucoma" continue to be primary resources for patients seeking to learn more about their glaucoma diagnosis, treatment options, and Glaucoma Research Foundation's research initiatives.

Speeding the Development of New Therapies
In 2012, thanks to the leadership of Drs. Adrienne Graves and Andrew G. Iwach, we launched the Glaucoma 360 New Horizons Forum, an annual meeting dedicated to advancing the development of new glaucoma therapies and diagnostic devices. This unique gathering of medicine, industry, finance, and the FDA is a catalyst to advance novel ideas into clinical practice and assist patients in the near term. These innovative initiatives are made possible through generous philanthropic support from individuals, foundations and corporations. Glaucoma Research Foundation receives no government funding and thanks to good financial stewardship, 85% of all funds raised go directly to funding research and education.

Please know that we are grateful for your participation in the 5th annual Glaucoma 360 and our efforts to eliminate this blinding disease. Thanks to you, the cure is truly in sight.

Fostering Collaborative Research
For more than three decades, Glaucoma Research Foundation has funded pioneering and transformational studies to advance the field of glaucoma. An important funding priority is fostering collaborative research in order to speed the pace of discovery. Landmark projects include the Collaborative Normal Tension Glaucoma Study, the first controlled clinical trial to establish that lowering eye pressure preserves vision, and the establishment of the Catalyst for a Cure (CFC) research consortium.

Established in 2001, our first CFC team focused on neuroprotection and fundamentally changed how the scientific and medical communities view vision loss in glaucoma. Based on this successful model, the second CFC team was recruited and charged with identifying new biomarkers to indicate the earliest signs of glaucoma. The impact of this research will be valuable for both patients and doctors as it has the potential to transform how glaucoma is diagnosed and managed in the future.

Thomas M. Brunner
President and Chief Executive Officer
WE’RE EXPANDING OUR FIELD OF VISION

Committed to Innovations in Eye Care

BAUSCH + LOMB

©Bausch & Lomb Incorporated. US/NPR/15/0029